PE20000348A1 - Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina - Google Patents

Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina

Info

Publication number: PE20000348A1
Authority: PE; Peru
Prior art keywords: statin; inhibitor; pharmaceutical composition; mmp; alkyl
Prior art date: 1998-03-17

Application number

PE1999000217A

Other languages

English (en)

Spanish (es)

Inventor

Bruce David Roth

Roger Schofield Newton

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-17

Filing date

1999-03-16

Publication date

2000-05-22

1999-03-16 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2000-05-22 Publication of PE20000348A1 publication Critical patent/PE20000348A1/es

Links

229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 2
239000003112 inhibitor Substances 0.000 title abstract 2
239000011159 matrix material Substances 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
FJLGEFLZQAZZCD-JUFISIKESA-N (3S,5R)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-JUFISIKESA-N 0.000 abstract 2
AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 abstract 2
AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 abstract 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 2
VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 abstract 1
-1 AMINO Chemical class 0.000 abstract 1
206010002383 Angina Pectoris Diseases 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
VGMFHMLQOYWYHN-UHFFFAOYSA-N Compactin Natural products OCC1OC(OC2C(O)C(O)C(CO)OC2Oc3cc(O)c4C(=O)C(=COc4c3)c5ccc(O)c(O)c5)C(O)C(O)C1O VGMFHMLQOYWYHN-UHFFFAOYSA-N 0.000 abstract 1
BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 1
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 abstract 1
TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 1
VXDSGTRNDFHIJB-QQPOVDNESA-N [(1s,4ar)-8-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1CCC[C@@H](C21)OC(=O)[C@@H](C)CC)=CC(C)C2CC[C@@H]1C[C@@H](O)CC(=O)O1 VXDSGTRNDFHIJB-QQPOVDNESA-N 0.000 abstract 1
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
230000003143 atherosclerotic effect Effects 0.000 abstract 1
229960005370 atorvastatin Drugs 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
229960005110 cerivastatin Drugs 0.000 abstract 1
SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 abstract 1
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
210000004351 coronary vessel Anatomy 0.000 abstract 1
229950003040 dalvastatin Drugs 0.000 abstract 1
VXDSGTRNDFHIJB-UHFFFAOYSA-N dihydrocompactin Natural products C12C(OC(=O)C(C)CC)CCCC2C=CC(C)C1CCC1CC(O)CC(=O)O1 VXDSGTRNDFHIJB-UHFFFAOYSA-N 0.000 abstract 1
229960003765 fluvastatin Drugs 0.000 abstract 1
235000019253 formic acid Nutrition 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
229960004844 lovastatin Drugs 0.000 abstract 1
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 abstract 1
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 abstract 1
229950009116 mevastatin Drugs 0.000 abstract 1
BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
229960002965 pravastatin Drugs 0.000 abstract 1
TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
229960002855 simvastatin Drugs 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PE1999000217A 1998-03-17 1999-03-16 Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina PE20000348A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7826598P	1998-03-17	1998-03-17

Publications (1)

Publication Number	Publication Date
PE20000348A1 true PE20000348A1 (es)	2000-05-22

Family

ID=22142950

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE1999000217A PE20000348A1 (es)	1998-03-17	1999-03-16	Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina

Country Status (18)

Country	Link
EP (1)	EP1063991A1 (fr)
JP (1)	JP2002506818A (fr)
KR (1)	KR20010041916A (fr)
AR (1)	AR018113A1 (fr)
AU (1)	AU1591699A (fr)
BR (1)	BR9815745A (fr)
CA (1)	CA2309588A1 (fr)
CO (1)	CO5070670A1 (fr)
GT (1)	GT199900039A (fr)
HN (1)	HN1999000029A (fr)
MY (1)	MY140504A (fr)
NZ (1)	NZ505994A (fr)
PA (1)	PA8469001A1 (fr)
PE (1)	PE20000348A1 (fr)
SV (1)	SV1999000026A (fr)
UY (1)	UY25436A1 (fr)
WO (1)	WO1999047138A1 (fr)
ZA (1)	ZA992106B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en)	2001-01-11	2001-02-21	Biocompatibles Ltd	Drug delivery from stents
RU2410118C2 (ru)	2004-12-15	2011-01-27	Зольвай Фармасьютиклз Гмбх	ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ НЭП (НЕЙТРАЛЬНОЙ ЭНДОПЕПТИДАЗЫ), ИНГИБИТОРЫ ЭНДОГЕННОЙ ПРОДУЦИРУЮЩЕЙ ЭНДОТЕЛИН СИСТЕМЫ И ИНГИБИТОРЫ ГМГ (ГИДРОКСИМЕТИЛГЛУТАРИЛ)СоА РЕДУКТАЗЫ
JP2009514851A (ja) *	2005-11-08	2009-04-09	ランバクシーラボラトリーズリミテッド	（３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
WO2010005389A1 (fr) *	2008-07-11	2010-01-14	Forskarpatent I Syd Ab	Protéines conjuguées ou fusionnées à un anticorps spécifique des protéines ldl oxydées

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU720853B2 (en) *	1995-11-02	2000-06-15	Warner-Lambert Company	Method and pharmaceutical composition for regulating lipid concentration
CN1077885C (zh) *	1996-05-17	2002-01-16	沃尼尔·朗伯公司	联苯基磺酰胺基质金属蛋白酶抑制剂
KR20000057444A (ko) *	1996-12-09	2000-09-15	로즈 암스트롱, 크리스틴 에이. 트러트웨인	심기능부전 및 심실확장의 치료 및 예방 방법
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) *	1997-08-29	2000-01-29		Terapia de combinacion.

1998
- 1998-11-20 EP EP98960279A patent/EP1063991A1/fr not_active Withdrawn
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 NZ NZ505994A patent/NZ505994A/xx unknown
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/ko not_active Ceased
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/ja active Pending
- 1998-11-20 CA CA002309588A patent/CA2309588A1/fr not_active Abandoned
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/pt not_active Application Discontinuation
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/fr not_active Ceased
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/es unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/es not_active Application Discontinuation
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/es not_active Application Discontinuation
- 1999-03-16 CO CO99016109A patent/CO5070670A1/es unknown
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/es unknown
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/es unknown
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/xx unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/es not_active Application Discontinuation
- 1999-03-16 GT GT199900039A patent/GT199900039A/es unknown

Also Published As

Publication number	Publication date
AU1591699A (en)	1999-10-11
NZ505994A (en)	2003-10-31
ZA992106B (en)	1999-09-30
EP1063991A1 (fr)	2001-01-03
GT199900039A (es)	2000-09-06
AR018113A1 (es)	2001-10-31
BR9815745A (pt)	2000-11-14
KR20010041916A (ko)	2001-05-25
WO1999047138A1 (fr)	1999-09-23
MY140504A (en)	2009-12-31
HN1999000029A (es)	1999-09-29
JP2002506818A (ja)	2002-03-05
CO5070670A1 (es)	2001-08-28
PA8469001A1 (es)	2002-09-17
CA2309588A1 (fr)	1999-09-23
SV1999000026A (es)	2000-01-18
UY25436A1 (es)	2001-10-25

Legal Events

Date	Code	Title	Description
2003-05-30	FG	Grant, registration
2006-10-18	FD	Application declared void or lapsed

Publication	Publication Date	Title
UY25159A1 (es)	2000-12-29	Composiciones farmacéuticas conteniendo amlodipino y una estatina
HRP20241674T1 (hr)	2025-02-14	6'-[[(1s,3s)-3-[[5-(difluormetoksi)-2-pirimidinil]amino]ciklopentil]amino][1(2h),3'-bipiridin]-2-on kao inhibitor pcsk9 i postupci njegove upotrebe
JP2022116083A5 (fr)	2023-01-20
BR9908690A (pt)	2000-12-05	Composição farmacêutica contendo estatina e aspirina
AR103624A1 (es)	2017-05-24	Composiciones farmacéuticas para terapia de combinación
JP2002501887A5 (ja)	2006-01-05	アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用
RU2012116079A (ru)	2013-10-27	Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина и способы ее применения
BG105559A (en)	2001-12-29	STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
DK0753298T3 (da)	2002-05-21	Synergistisk kombination, der omfatter et insulinsensibiliserende middel og en HMG-CoA-reduktaceinhibitor til behandling af arteriosklerose
JP2018504438A5 (fr)	2019-02-14
TR200302281T2 (tr)	2004-09-21	Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler
AR081032A1 (es)	2012-05-30	Formulacion farmaceutica en forma de comprimidos de dos capas que comprenden inhibidor de hmg-coa reductasa e irbesartan
PE20001047A1 (es)	2000-12-24	METODO PARA TRATAR ATEROESCLEROSIS EMPLEANDO UN INHIBIDOR DE aP2 Y COMBINACION
PE20000017A1 (es)	2000-01-20	Combinaciones de estatina-eter carboxialquilico
DK1626716T3 (da)	2007-05-14	Nitrooxyderivater af fluvastatin, pravastatin, cerivastatin, atorvastatin og rosuvastatin som cholesterol-sænkende midler med forbedret anti-inflammatorisk, antithrombotisk og anti-blodplade-aktivitet
PE20000348A1 (es)	2000-05-22	Composicion farmaceutica que comprende un inhibidor de metaloproteasa de matriz (mmp) y una estatina
ATE409485T1 (de)	2008-10-15	Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
JP2007512347A5 (fr)	2008-01-17
AR080023A1 (es)	2012-03-07	Formulacion de complejos que comprende aspirina revestida con una barrera que contiene aditivo hidrofobo e inhibidor de la hmg-coa reductasa
JP2002508320A5 (fr)	2006-01-19
CY1105429T1 (el)	2010-04-28	Φαρμακευτικη συνθεση συνδυαζουσα τενατοπραζολη και ενα αντιφλεγμονωδες
BR0215602A (pt)	2004-12-07	ésteres de boronato
JP2007530528A5 (fr)	2008-05-08
RU2351329C2 (ru)	2009-04-10	Ингибиторы кинуренин 3-гидроксилазы для лечения диабета
UY29979A1 (es)	2007-06-29	Derivados espirociclicos